We have a non-exclusivity agreement with Gilead, I think. So we have a much broader market than what we may have under the GILD umbrella.
And I just can't help but think a buyout would result in a double digit share price, whereas we may have more upside potential as a stand-alone entity.
I was disappointed with the possibility that we may have only enrolled 113 patients for our P3 at this point. I hope that is not accurate. I'm basing this on slide 10.
"Lenzilumab shown to be safe in clinical settings following administration to 125 patients (note 1) in multiple indications (including severe respiratory conditions and leukemia) with no serious adverse events...
(note 1 Includes 12 Compassionate Use patients)" edited for clarity
Market Data 
Markets 
AI
